Depression That Doesn’t Respond to Antidepressants: What Comes Next?

About one in three people treated for major depressive disorder do not respond adequately to antidepressants, a pattern clinicians call treatment-resistant depression (National Institutes of Health). This is not a matter of willpower, and it is not a sign that the depression cannot be treated. It means the neurobiology driving it may require a different approach than the one that works for most people.

What Treatment-Resistant Depression Actually Means

The term gets used loosely, but clinically it has a specific meaning. Treatment-resistant depression is a major depressive episode that has not responded adequately to at least two antidepressant medications at therapeutic doses, taken for a sufficient duration, typically six to eight weeks each (National Institutes of Health). This distinction separates patients who may simply need a different medication from patients who need a fundamentally different kind of treatment.

Several factors contribute to why some depression resists standard antidepressants. Genetic variations in how individuals metabolize medication can make standard doses ineffective or poorly tolerated before they have a chance to work. Underlying conditions such as thyroid dysfunction, chronic inflammation, or sleep disorders can sustain depressive symptoms independently of serotonin-targeted treatment. For some patients, the neurobiology of their depression involves systems that SSRIs and SNRIs simply do not address directly. Understanding which of these factors applies to a given patient is the necessary starting point for any meaningful next step.

What Depression Looks Like When Medications Have Not Worked

Major depressive disorder affects mood, energy, sleep, appetite, concentration, and interest in activities a person previously valued (Mayo Clinic). When antidepressants work, these symptoms ease significantly over the course of weeks. When they do not, patients are often left managing the same symptoms while also carrying the discouragement of treatment that did not deliver.

For some patients, this looks like cycling through several antidepressants over months or years without finding one that works. For others, it looks like partial improvement that never gets all the way there. For others still, it looks like side effects that made the medication intolerable before it had a chance to demonstrate whether it would help. All of these experiences fall within the same broad category of inadequate response, and all of them are worth taking seriously as clinical information rather than a verdict.

Why Newer Options Exist

Research into treatment-resistant depression has moved quickly in recent years. Rapid-acting treatments that work through different neurological pathways than standard antidepressants have demonstrated significant results for patients who have not responded to conventional options (National Institute of Mental Health, 2024). These treatments do not target the serotonin or norepinephrine systems that SSRIs and SNRIs rely on. They act through the glutamate system, the brain’s primary excitatory neurotransmitter pathway, and some produce effects in hours rather than weeks.

This research established the clinical basis for SPRAVATO® and IV ketamine as options for treatment-resistant depression, both of which we offer at DreamWork Wellness Center. It also helped explain why some patients who do not respond to conventional medications respond to these newer approaches: the neurobiology of their depression may not be located in the systems that standard medications reach.

What We Offer at DreamWork

At our Frisco and Sherman, TX locations, we offer several evidence-based options for patients with treatment-resistant depression.

SPRAVATO® is an FDA-approved nasal spray formulation of esketamine, available only through certified healthcare providers. It works through the glutamate system and is the first medication of its kind approved specifically for TRD. Treatment involves monitored sessions at our clinic and is covered by most major insurance plans when clinical criteria are met.

TMS therapy uses focused magnetic pulses to stimulate specific regions of the brain associated with mood regulation, without sedation, anesthesia, or systemic medication. The FDA cleared TMS for major depressive disorder in 2008. At DreamWork, we use the NeuroStar Advanced TMS system at both our locations.

IV ketamine therapy is also available and may be considered for patients who have not responded to other treatments. Ketamine acts rapidly through the glutamate system and is administered intravenously in a clinical setting. Candidates are evaluated thoroughly before treatment is recommended.

Medication management through our psychiatry team may identify approaches that have not yet been tried, including augmentation strategies, medication combinations, or a review of prior trials to assess whether dosing or duration were adequate. Our medical director, Dr. Jahi Anderson, is a board-certified psychiatrist with more than fifteen years of experience specifically in treatment-resistant mood and anxiety disorders.

What the Evaluation Process Looks Like

Before recommending any of these options, we conduct a thorough psychiatric evaluation that reviews your full treatment history: what you have tried, for how long, at what doses, and how you responded. We also screen for medical factors that can sustain depression independently of the treatments tried so far. The evaluation does not assume you need any particular treatment. It starts with what we do not yet know and builds from there.

Results vary by individual. There is no single approach that works for every patient with treatment-resistant depression, which is why the evaluation is not optional. What we can tell you is that most patients who come to us have not exhausted all available options, even when it feels that way.

On Cost and Insurance

We accept all major insurance plans at DreamWork, including Medicare, Blue Cross Blue Shield, Aetna, UnitedHealthcare, Cigna, United Medical Resources, Magellan, and TriWest Healthcare Alliance. SPRAVATO® and TMS are both covered by many major plans when clinical criteria are met. Our team handles prior authorization and insurance verification for both before treatment begins so you know your costs before committing to anything. Call us at 214-592-8159 with any questions about coverage.

Frequently Asked Questions

How do I know if I qualify as treatment-resistant?

The clinical threshold is generally two or more antidepressant trials at adequate doses for adequate duration without sufficient response. If you are unsure whether your prior medication trials meet that standard, a psychiatric evaluation will clarify that. Some patients who believe they are treatment-resistant have not completed a full therapeutic trial at the right dose and duration. Others clearly meet the criteria from their history alone. The evaluation is the right starting point either way.

What is the difference between TMS and SPRAVATO® for treatment-resistant depression?

Both are FDA-approved or FDA-cleared for depression and both work through mechanisms different from standard antidepressants. TMS uses magnetic pulses delivered to the scalp with no medication involved; SPRAVATO® is a nasal spray administered in a monitored clinical setting. They have different side effect profiles, different treatment schedules, and different insurance coverage considerations. Discussing your history and preferences with your provider is the best way to determine which is more appropriate for your situation.

Are there treatments that work faster than antidepressants?

SPRAVATO® and IV ketamine have both demonstrated antidepressant effects that can occur within hours in some patients, which is significantly faster than the four-to-eight-week timeline associated with standard antidepressants (National Institute of Mental Health, 2024). Results vary by individual, and rapid onset does not apply to every patient. TMS typically requires several weeks of daily sessions before its full effect becomes apparent.

What if I have tried multiple treatments and nothing has worked?

Patients who have been through multiple treatment failures often arrive at this question with real exhaustion, and that is understandable. Our honest answer is that the range of available options for treatment-resistant depression has expanded considerably in the past decade, and most patients who come to us have not tried all of them. We discuss that openly at every evaluation. We do not guarantee outcomes, but we do offer a thorough, evidence-based assessment of what has and has not been ruled out.

Do I need a referral to be seen at DreamWork?

No referral is required. DreamWork has licensed psychiatric providers on staff who can assess candidacy directly. Call us at 214-592-8159 or reach out through our website to schedule a consultation.

Key Takeaways

• Treatment-resistant depression is defined clinically as inadequate response to two or more antidepressant trials at therapeutic doses. It is a clinical designation, not a verdict on whether recovery is possible.
• Standard antidepressants primarily target the serotonin and norepinephrine systems. TRD often involves other neurological pathways, which is why different treatment approaches produce results where conventional medications have not.
• At DreamWork, evidence-based options for TRD include SPRAVATO®, TMS therapy, IV ketamine, and comprehensive medication management and psychiatry.
• A thorough evaluation of your full treatment history is the required first step before any advanced treatment is recommended. Results vary by individual.
• DreamWork accepts all major insurance plans. SPRAVATO® and TMS are both covered by many plans when clinical criteria are met, and our team handles prior authorization before treatment begins.

A History of Failed Antidepressants Is Information, Not a Verdict

The fact that standard treatment has not worked tells us something specific about the neurobiology of your depression. At DreamWork Wellness Center, our team in Frisco and Sherman, TX starts every evaluation by taking that history seriously and asking what it tells us about where to go next. Call us at 214-592-8159 or reach out through our website to schedule a consultation. Bring your full treatment history, and we will give you a direct answer about what has not been tried yet.